Health Condition 1: C7A8- Other malignant neuroendocrine tumors
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Mahamana Pandit Madan Mohan Malviya Cancer Centre
Eligibility
Inclusion criteria
Inclusion criteria: INCLUSION CRITERIA: For group of patients who developed toxicity post-irinotecan: Histopathological confirmed incident cases of Neuroendocrine Carcinomas undergoing chemotherapy who reported toxicity after chemotherapy during the study period. For group of patients who did not develop toxicity post-irinotecan: Histopathological confirmed incident cases of Neuroendocrine carcinomas undergoing chemotherapy without any reported toxicity after chemotherapy during the study period.
Exclusion criteria
Exclusion criteria: Patients less than 18 years of age Pregnant and Lactating patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome - Proportion of NEC patients on Irinotecan that had polymorphism of UGT11A1 among the cases and controlsTimepoint: All enrolled participants will be assessed for the outcomes after the completion of chemotherapy cycles that is after3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of the UGT1A1 polymorphism, toxicity with other variables collected in the study.Timepoint: Will be assessed after 3 months of enrollment of the patient that is after completion of chemotherapy | — |
Countries
India
Contacts
Public ContactPratibha Gavel
Homi Bhabha Cancer Hospital , Varanasi
Outcome results
None listed